Add-on bevacizumab can prevent early clinical deterioration and prolong survival in newly diagnosed partially resected glioblastoma patients with a poor performance status

PURPOSE: The AVAglio trial established the beneficial effect of add-on bevacizumab (BEV) for the treatment of newly diagnosed glioblastomas (nd-GBMs) that led to the approval of BEV for the treatment of these patients in Japan. However, the rationality of using BEV as a first-line treatment for nd-G...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Onco Targets Ther
Main Authors: Hata, Nobuhiro, Yoshimoto, Koji, Hatae, Ryusuke, Kuga, Daisuke, Akagi, Yojiro, Sangatsuda, Yuhei, Suzuki, Satoshi O, Shono, Tadahisa, Mizoguchi, Masahiro, Iihara, Koji
Formato: Artigo
Idioma:Inglês
Publicado em: Dove Medical Press 2017
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5261854/
https://ncbi.nlm.nih.gov/pubmed/28176936
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S125587
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados